Overview

An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study

Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
An Open-label, Randomized, 2-Period, Crossover Study to Assess the Comparative Pharmacokinetics of LSP-5415 and NuvaRing® in Healthy Adult Females
Phase:
Phase 2
Details
Lead Sponsor:
Lupin Research Inc
Treatments:
Estradiol
Ethinyl Estradiol
Etonogestrel
NuvaRing